Relationship Between Nucleos(t)ide analogue antiviral response time and prognosis in Chronic Hepatitis B: conclusions depend on baseline viral load and HBeAg status

• DOI: 10.3389/fphar.2025.1572827
• Publication Date: 2025-04-24T04:11:48Z
• Authors: Jingtao Huang; Xiangyong Li; Lijie You; Yutian Chong; Hong Cao
• Keywords: HBeAg; Baseline (sea); Antiviral Therapy; Hepatitis B

Current guidelines for changing antiviral therapy regimens do not consider different baseline statuses. This study aimed to investigate whether significant prognostic differences exist among patients achieving virological response at various time points and these vary by viral load HBeAg status. retrospective cohort included 1,037 patients, who were classified based on their (high load, HVL, ≥ 7log10 IU mL-1: 522 individuals; or non-HVL, < 515 individuals) status (positive: 668 negative: 369 individuals). Based the time, grouped separately using 48 weeks 96 as boundaries. The prognoses across groups evaluated compared. Patients in within-48-week group, 48-96-week after-96-week group exhibited no difference incidence of liver disease progression (5.08% vs 4.38% 9.61%, p = 0.33). For HVL HBeAg-positive there was cumulative between group. In contrast, non-HVL HBeAg-negative significantly higher after-48-week than Only showed a increase maintained rate (p 0.04). Antiviral treatment should be adjusted patients. we suggest plan weeks.